|Day Low/High||360.01 / 377.80|
|52 Wk Low/High||196.78 / 380.76|
This week's introduction of the NovaSeq Series of genomic sequencers caused the stock to jump.
Do that if you like top ticking crowd favorites, but set a protective stop.
If Twitter puts up a dreadful quarter, shares will sell off again.
The media is not the message. With a little help from Johnny Mercer, did you know he founded Capitol Records? This is serious folks -- I see less of a reason to have an outsized long portfolio than at any time since Winter 2007. The market outlook...
On days like this, the money just keeps sloshing around.
U.S. stocks slipped after a disappointing quarterly performance from Alcoa soured optimism over earnings season.
Cantor Fitzgerald says Illumina's outlook revision is not likely to affect industry peers.
Shares of Illumina were tanking before the opening bell after unveiling a disappointing sales forecast.
Back from my meetings to find the S&P 500 Index basically traded in a 2-3 point range over the last four hours, which is a statistically improbable event! Highs were made early in the day when I issued my Trade of the Week (short SPDR S&P 500 ETF ...
I have been a big bull on its technology, but I am sidelined right now.
Lots of energy names facing the potential for lower prices.
Following the positive action over the last four days, an upside resolution now appears likely.
Charts show ILMN is close to offering a great profit opportunity.
ILMN's three-month at-the-money implied volatility is at about the median level.
With very low oversold readings and a possible reversal pattern, we would at least cover shorts, and would consider probing the long side.
My thoughts on the day: The five-day market win streak stalled a bit today. Though the close was weak, I still give the win to the bulls because of the modest drop in the averages after an 80-handle rise in the S&P index. That said, there was less t...
Take advantage of elevated option premiums to gain long exposure to biotech.
DNA sequencing company Illumina (ILMN) plummeted in midday trading Tuesday after reporting disappointing preliminary sales for its third quarter.
With such a commanding lead in the sequencing business the stock can't stay down for long.